Page 16 - DIAGEN

Hermatology primeFISH Products

HEMATOLOGY

PANEL

17-002 MLL (11q23) Breakapart

Up to 1-15% of cancer patients treated with KMT2A gene documented tor KMT2A; the most common translocations
rearrangements with a DNA topoisomer ase il inhibitor are t(4;11) and t(ll;l9) in ALL patients, t(6;11), t(9;11) and
develop therapy-associated leukemia (t-AML) associated t(ll;l9) in AML patients. Overall, the finding of KMT2A re-
with KMT2A transloca tions. Translocations involving the arrangements in patients with acute leukemia indicates a
KMT2A gene are detected in 5-6% of all acute myeloid less favorable prognosis. However, recent studies suggest
leuke mias (AML) and 5-10% of ali acute lymphoblastic that the specific KMT2A translocation partner may have
leukemias (ALL). The frequency of translocations involving an impact on response to therapy and overall prognosis,
the KMT2A gene is significantly higher in infants with AML depending on the clinical concept.
(50%) and ALL (80%). Over 30 fusion partners have been

BREAKAPART

RH52370 RH99291 RH52087 RH93709
5' 3' NORMAL
Gen Tel
KMT2A

730 kb 821 kb

DELETION

11q23.3
(Not to scale)

www.diagen.com.tr References
Gindin T, et al. (2015) Hematol Oncol 33(4) 239-46.
Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The AGT Cytogenetics Laboratory Manual. New Jersey: John Wiley & Sons Inc.
Burns et al (2018) Hematology (7th ed) Ch 64: Pathobiology of acute lymphoblastic leukemia:1005–1019.e11

16 PRODUCT CATALOGUE info@diagen.com.tr